Inogen reports Q4 EPS (41c) vs ($1.14) last year

Reports Q4 revenue $80.1M, consensus $73.9M. “2024 was a stellar year for Inogen (INGN). With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability,” said Kevin Smith, President and Chief Executive Officer. “With our leading portfolio of innovative respiratory care products, the pending introduction of Simeox in the U.S. and our recently announced collaboration with Yuwell, we believe we are well positioned to drive future growth, profitability and sustained success.”